Pfizer Painkiller Gets Longer Patent Protection

Pfizer could gain an additional 18 months of U.S. exclusivity—and monopoly sales—for its painkiller Celebrex because the government effectively reinstated a patent whose claims were previously struck down in court.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news